Drug Type TCR-T Cell therapy |
Synonyms Neoantigen Targeted TCR-T |
Target |
Action inhibitors |
Mechanism Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of Lung | Phase 2 | United States | 04 Apr 2022 | |
Bile Duct Neoplasms | Phase 2 | United States | 04 Apr 2022 | |
Colorectal Cancer | Phase 2 | United States | 04 Apr 2022 | |
Endometrial Carcinoma | Phase 2 | United States | 04 Apr 2022 | |
Ovarian Cancer | Phase 2 | United States | 04 Apr 2022 | |
Pancreatic Cancer | Phase 2 | United States | 04 Apr 2022 | |
squamous cell lung carcinoma | Phase 2 | United States | 04 Apr 2022 |